Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

Inotuzumab ozogamicin (InO), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, has demonstrated efficacy in the phase 3 INO-VATE study of adults with relapsed or refractory acute lymphoblastic leukemia (ALL). Findings from the study showed clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kebriaei, Partow, Cutler, Corey, de Lima, Marcos, Giralt, Sergio, Lee, Stephanie J., Marks, David, Merchant, Akil, Stock, Wendy, van Besien, Koen, Stelljes, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897380/
https://www.ncbi.nlm.nih.gov/pubmed/29330398
http://dx.doi.org/10.1038/s41409-017-0019-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897380/
https://www.ncbi.nlm.nih.gov/pubmed/29330398
http://dx.doi.org/10.1038/s41409-017-0019-y

Ejemplares similares